 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C23H26N2O |
| Molar mass | 346.474 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-CBMICA (SGT-280) is anindole-3-carboxamide basedsynthetic cannabinoid receptor agonist which has been sold as adesigner drug,[1][2] first being identified in Germany in August 2019. Since the structure fell outside the German drug analogue law provisions at the time, an amendment was made to the law to expand the relevant definition, which came into effect in April 2020.[3] It has been shown to act as a CB1 receptor agonist with an EC50 of 62.9nM.[4]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |
